2-[(3,4-Dichlorophenyl)methyl]-6-[(E)-2-phenylethenyl]-2,3,4,5-tetrahydropyridazin-3-one

Catalog No. :
ACFNPG810
CAS No. :
1164529-92-3
Molecular Formula :
C19H16Cl2N2O
Molecular Weight :
359.26

IUPAC Name:(E)-2-(3,4-dichlorobenzyl)-6-styryl-4,5-dihydropyridazin-3(2H)-one

2-[(3,4-Dichlorophenyl)methyl]-6-[(E)-2-phenylethenyl]-2,3,4,5-tetrahydropyridazin-3-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$563.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[(3,4-Dichlorophenyl)methyl]-6-[(E)-2-phenylethenyl]-2,3,4,5-tetrahydropyridazin-3-one
IUPAC Name(E)-2-(3,4-dichlorobenzyl)-6-styryl-4,5-dihydropyridazin-3(2H)-one
MDL No.MFCD00793325
Molecular FormulaC19H16Cl2N2O
Molecular Weight359.26
SMILESO=C1CCC(/C=C/C2=CC=CC=C2)=NN1CC3=CC=C(Cl)C(Cl)=C3
InChI KeyUGQLQYCGDGFRJZ-SOFGYWHQSA-N
Synonym2-(3,4-DICHLOROBENZYL)-6-STYRYL-4,5-DIHYDRO-3(2H)-PYRIDAZINONE;3(2H)-Pyridazinone, 2-[(3,4-dichlorophenyl)methyl]-4,5-dihydro-6-[(1E)-2-phenylethenyl]-
CAS No.1164529-92-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACFNPG810 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFNPG810 route product structure diagram
    ACFNPG8101164529-92-3
Inquiry

2. ACFNPG810 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFNPG810 route product structure diagram
    ACFNPG8101164529-92-3
Inquiry

Comments (0)